Here are some of the major companies whose stocks moved on the week's news.

The company has beat EPS estimates in 4 of the last 5 years and has delivered five straight quarters ... Ferrari, and Merck centralize, manage, and analyze data. Apollo facilitates frictionless ...

The company is already developing gene therapies delivered to their bodily destinations ... A Phase 3 study is evaluating Padcev in combination with the Merck immunotherapy Keytruda as a treatment ...

Representative Kelly Morrison, never one to keep her portfolio on cruise control, sold up to $15,000 in United Parcel Service ...

Last week, Merck entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this ...

Cyprumed may receive up to $493 million in milestone payments from Merck for peptide drug delivery tech. Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

In 4Q24, Merck delivered 7% y/y sales growth to $15.6bn, with new launches contributing $900m (+140% y/y) and leading immunotherapy KEYTRUDA sustaining 11% growth despite increasing biosimilar ...